ArticleBiochemical genetics2026
GSDME Deficiency Suppresses ER Stress-Induced Autophagic Cell Death via mTOR/S6K1 Activation in Hepatobiliary Carcinomas.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- mTOR signaling in cholangiocarcinoma: mechanistic insights and therapeutic opportunities.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Endoplasmic reticulum (ER) stress activation triggers programmed cell death through coordinated autophagy and apoptosis pathways. Although Gasdermin E (GSDME) is established as a pyroptosis executor and tumor suppressor, its regulatory role in ER stress-mediated autophagy remains unknown. In this study, we identify GSDME as a critical modulator of autophagic flux during ER stress-induced cell death. Using the novel GRP78 inhibitor YUM70, we demonstrate potent antitumor activity in cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC) models through ER stress-mediated autophagy, characterized by elevated LC3-II/I ratios and caspase-3/PARP activation. Paradoxically, YUM70 treatment induced dose-dependent GSDME downregulation across hepatobiliary cancer cells. Genetic ablation of GSDME significantly attenuated YUM70-induced autophagic death via reactivation of the mTOR/S6K1 signaling axis. Mechanistically, GSDME maintains autophagic flux by suppressing mTOR-mediated lysosomal biogenesis during ER stress. These findings unveil a non-canonical function of GSDME as an autophagy rheostat and provide mechanistic insights into chemotherapy resistance in GRP78-targeted therapies. Our work establishes GSDME expression status as a predictive biomarker and therapeutic target for hepatobiliary malignancies undergoing ER stress modulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.